{"id":22808,"date":"2021-12-16T13:04:00","date_gmt":"2021-12-16T13:04:00","guid":{"rendered":"https:\/\/celonpharma.com\/?p=22808"},"modified":"2022-01-18T13:08:03","modified_gmt":"2022-01-18T13:08:03","slug":"current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\/","title":{"rendered":"Current report No. 55\/2021 \u2013 Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd."},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Date prepared: December 16, 2021, time: 02:24 PM<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Abbreviated name of the issuer: Celon Pharma S.A.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Subject: Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 inside information.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Content of the report:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In connection with current report No. 13\/2021 K on Celon Pharma S.A. (\u201cCompany\u201d) and Glenmark Pharmaceuticals Ltd with its registered seat in India concluding a licence agreement (\u201cAgreement\u201d) concerning cooperation in the registration, sale and distribution of a product that constitutes a combination of fluticasone and salmeterol in a dry powder inhaler (sold under the name Salmex in Poland), the Management Board of the Company hereby informs that an amendment to the aforementioned Agreement expanding its territorial scope to include Australia has been signed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The amendment was concluded for a period of 10 years from the date of sales commencement in the given market, with the possibility of extension.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In connection with current report No. 13\/2021 K on Celon Pharma S.A. (\u201cCompany\u201d) and Glenmark Pharmaceuticals Ltd with its registered seat in India concluding a licence<\/p>\n","protected":false},"author":20,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[46],"tags":[],"class_list":["post-22808","post","type-post","status-publish","format-standard","hentry","category-current-reports"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Current report No. 55\/2021 \u2013 Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd. - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current report No. 55\/2021 \u2013 Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd. - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"In connection with current report No. 13\/2021 K on Celon Pharma S.A. (\u201cCompany\u201d) and Glenmark Pharmaceuticals Ltd with its registered seat in India concluding a licence\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-16T13:04:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-18T13:08:03+00:00\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\\\/\"},\"author\":{\"name\":\"Ma\u0142gorzata Siewierska\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"headline\":\"Current report No. 55\\\/2021 \u2013 Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd.\",\"datePublished\":\"2021-12-16T13:04:00+00:00\",\"dateModified\":\"2022-01-18T13:08:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\\\/\"},\"wordCount\":168,\"articleSection\":[\"Current reports\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\\\/\",\"name\":\"Current report No. 55\\\/2021 \u2013 Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd. - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2021-12-16T13:04:00+00:00\",\"dateModified\":\"2022-01-18T13:08:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Current report No. 55\\\/2021 \u2013 Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\",\"name\":\"Ma\u0142gorzata Siewierska\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current report No. 55\/2021 \u2013 Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd. - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\/","og_locale":"en_US","og_type":"article","og_title":"Current report No. 55\/2021 \u2013 Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd. - Celon Pharma","og_description":"In connection with current report No. 13\/2021 K on Celon Pharma S.A. (\u201cCompany\u201d) and Glenmark Pharmaceuticals Ltd with its registered seat in India concluding a licence","og_url":"https:\/\/celonpharma.com\/en\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\/","og_site_name":"Celon Pharma","article_published_time":"2021-12-16T13:04:00+00:00","article_modified_time":"2022-01-18T13:08:03+00:00","author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\/"},"author":{"name":"Ma\u0142gorzata Siewierska","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"headline":"Current report No. 55\/2021 \u2013 Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd.","datePublished":"2021-12-16T13:04:00+00:00","dateModified":"2022-01-18T13:08:03+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\/"},"wordCount":168,"articleSection":["Current reports"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\/","url":"https:\/\/celonpharma.com\/en\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\/","name":"Current report No. 55\/2021 \u2013 Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd. - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2021-12-16T13:04:00+00:00","dateModified":"2022-01-18T13:08:03+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/current-report-no-55-2021-expansion-of-the-territorial-scope-of-the-licence-agreement-with-glenmark-pharmaceuticals-ltd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Current report No. 55\/2021 \u2013 Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd."}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c","name":"Ma\u0142gorzata Siewierska"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/22808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=22808"}],"version-history":[{"count":2,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/22808\/revisions"}],"predecessor-version":[{"id":22810,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/22808\/revisions\/22810"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=22808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=22808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=22808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}